Anixa Biosciences (NASDAQ:ANIX – Get Free Report) announced its quarterly earnings data on Friday. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02, Zacks reports.
Anixa Biosciences Stock Performance
NASDAQ:ANIX opened at $2.25 on Friday. The company has a market capitalization of $72.40 million, a P/E ratio of -5.77 and a beta of 0.90. The firm has a 50-day moving average price of $2.92 and a two-hundred day moving average price of $3.02. Anixa Biosciences has a twelve month low of $2.14 and a twelve month high of $5.13.
Analysts Set New Price Targets
Several research analysts have issued reports on ANIX shares. HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Anixa Biosciences in a research report on Tuesday, November 19th. D. Boral Capital restated a “buy” rating and issued a $10.00 price target on shares of Anixa Biosciences in a research report on Tuesday, November 19th.
Anixa Biosciences Company Profile
Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.
Read More
- Five stocks we like better than Anixa Biosciences
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Goldman Sachs Unveils 3 Massive Opportunities for 2025 Investors
- What is a support level?
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- What is the Euro STOXX 50 Index?
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
